European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
This second section of the European Crohn's and Colitis Organisation (ECCO) Consensus on the management of Crohn's disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohn's disease. The third section on special situations in Crohn's disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohn's disease.
John Radcliffe Hospital, Oxford OX3 9DU, UK. simon.travis@orh.nhs.uk
S P L
SP
Travis
E F
EF
Stange
M
M
Lémann
T
T
Oresland
Y
Y
Chowers
A
A
Forbes
G
G
D'Haens
G
G
Kitis
A
A
Cortot
C
C
Prantera
P
P
Marteau
J-F
JF
Colombel
P
P
Gionchetti
Y
Y
Bouhnik
E
E
Tiret
J
J
Kroesen
M
M
Starlinger
N J
NJ
Mortensen
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D004351:Drug Resistance; D019317:Evidence-Based Medicine; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D018579:Patient Selection; D011687:Purines / Q000627:therapeutic use; D012074:Remission Induction; D055502:Secondary Prevention
D000305:Adrenal Cortex Hormones; D000636:Aminosalicylic Acids; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D011687:Purines; D000069285:Infliximab; D008727:Methotrexate